Imsidolimab is a monoclonal antibody that inhibits interleukin-36 receptor signaling and is administered intravenously.

In adults with psoriasis, ustekinumab showed the highest drug survival rate in biologic-naive patients but had reduced effectiveness in biologic-experienced patients.

Conclusions: With the development of recombinant DNA techniques, it has become possible to develop new biologic therapies that can be designed to specifically alter physiological responses. These new ...

Interleukin-23 inhibitors, prior treatment history, and Psoriasis Area and Severity Index scores may be predictive of time to disease relapse among patients with psoriasis who achieved clinical ...

Patients with psoriasis who have active cancer or who have had cancer within 5 years can safely use biologics.

Maintenance therapy with subcutaneous imsidolimab allowed all treated patients to remain flare-free throughout the GEMINI-2 study period.

Black patients on Medicaid less likely to use the newer therapies ...

Please provide your email address to receive an email when new articles are posted on . Understanding drug survival is important for clinical prescribing and long-term disease control. Bimekizumab has ...

Higher BMI, BMR, BSA, and weight correlate with more severe psoriasis and reduced treatment efficacy, particularly with biologic therapies. Personalized dosing strategies may be necessary for biologic ...

Combination ixekizumab plus tirzepatide outperformed ixekizumab monotherapy for the treatment of both psoriasis and overweight or obesity, according to topline results announced by Eli ...

Some 25% of patients with psoriasis eventually develop psoriatic arthritis, but the risk may be mitigated with targeted therapies. This single-center study found that progression to PsA was more ...